Regenerative Therapeutics Target health systems and biopharma partners seeking innovative regenerative macrophage therapies for inflammatory and fibrotic diseases, with immediate interest in liver disease and expanding to lung fibrosis and other indications.

Clinical Stage Opportunity Position Resolution Therapeutics as a clinical-stage partner for collaboration or out-licensing of RTX001 and enhanced RMT approaches to biotechs and larger pharma seeking late-stage development capabilities and clear IP strategy.

Strategic Partnerships Leverage backing from Syncona and university-origin IP to attract academic collaborations, contract research arrangements, and joint development deals with institutions focused on regenerative medicine and fibrosis research.

Regulatory & Funding Readiness Highlight ongoing preclinical progress, upcoming conference data (ASGCT) and Liver Meeting presentations to engage investors and potential sponsors, while signaling readiness for future funding rounds or milestone-based partnerships.

Global Market Expansion Emphasize the high and growing demand for transplant alternatives in Western markets, offering a compelling value proposition to health systems and payers for reduced transplant need, improved quality of life, and potential long-term cost savings.